{"product_id":"pt-141-bremelanotide-pen","title":"PT-141 |15 mg pen","description":"\u003cp\u003e\u003cstrong\u003ePT-141 (Bremelanotide)\u003c\/strong\u003e is a peptide positioned for controlled research settings where \u003cstrong\u003ecentral melanocortin-driven arousal signaling\u003c\/strong\u003e is being studied in relation to \u003cstrong\u003esexual desire and distress endpoints\u003c\/strong\u003e, \u003cstrong\u003ehypothalamic circuit activation\u003c\/strong\u003e, and \u003cstrong\u003ereward-linked neurotransmitter modulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eCentral arousal signaling and sexual desire scoring endpoints (model-dependent)\u003c\/li\u003e\n\u003cli\u003eMelanocortin receptor (MC3R\/MC4R) pathway engagement in hypothalamic circuits\u003c\/li\u003e\n\u003cli\u003eReward-circuit neurotransmitter modulation linked to motivational behavior readouts\u003c\/li\u003e\n\u003cli\u003eSexual distress and satisfaction-related outcome measures in controlled cohorts\u003c\/li\u003e\n\u003cli\u003eNeurobehavioral arousal integration independent of peripheral vasodilation mechanisms\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003ePT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from α-MSH analog research, developed to probe central mechanisms of sexual motivation and arousal. In contrast to agents that primarily act on peripheral vascular pathways, PT-141 is studied as a CNS-active compound engaging melanocortin signaling in hypothalamic and limbic networks associated with desire and motivational drive.\u003c\/p\u003e\n\u003cp\u003eIn human clinical research, bremelanotide has been evaluated using validated desire and distress instruments, with outcomes typically interpreted as changes in central arousal signaling rather than direct smooth muscle relaxation. Preclinical literature supports a mechanistic focus on MC4R\/MC3R-linked circuitry, including hypothalamic neuronal activation and downstream neurotransmitter effects relevant to arousal-state transitions.\u003c\/p\u003e\n\u003cp\u003ePT-141 is presented on Peptoora for research positioning only, where experimental designs can examine melanocortin receptor pharmacology, circuit-level activation patterns, and behavioral endpoints under controlled conditions.\u003c\/p\u003e\n\u003ch2\u003eClinical Status\u003c\/h2\u003e\n\u003cp\u003ePT-141 (bremelanotide) has been evaluated in multiple controlled human trials for sexual desire endpoints and has been approved in certain jurisdictions for a specific indication in female sexual desire disorders. Mechanistic understanding is supported by animal and translational neuroscience studies that characterize melanocortin receptor signaling and hypothalamic circuit engagement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003eHuman RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ✔\u003c\/p\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"4079a05\" class=\"elementor-element elementor-element-4079a05 color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cp\u003eClinically evaluated and approved in certain jurisdictions for specific sexual desire indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"menu-anchor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"00869ec\" class=\"elementor-element elementor-element-00869ec elementor-widget elementor-widget-menu-anchor\"\u003e\n\u003cdiv id=\"2\" class=\"elementor-menu-anchor\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003ePT-141 acts as a melanocortin receptor agonist with research emphasis on MC4R and MC3R signaling within hypothalamic and limbic regions. In experimental paradigms, melanocortin activation is associated with changes in motivational circuitry, including modulation of dopamine-linked reward processing and arousal-state signaling, which are commonly used as mechanistic endpoints in sexual function research.\u003c\/p\u003e\n\u003cp\u003eUnlike PDE-5 inhibitors that target peripheral nitric oxide\/cGMP pathways, PT-141 is positioned as acting upstream at the level of central desire circuitry. Studies often evaluate its effects through neurobehavioral readouts, hypothalamic activation markers, and validated patient-reported outcome measures, recognizing that magnitude and timing of effects are context- and model-dependent.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eCentral Activation Of Sexual Motivation Circuits:\u003c\/b\u003e\u003cbr\u003ePT-141 has been studied for its ability to activate melanocortin receptors within hypothalamic nuclei associated with sexual motivation and arousal behavior. Unlike peripheral vasodilators, this peptide acts directly on central neural circuits governing desire. Clinical trials demonstrate ↑ sexual desire scores and ↑ frequency of satisfying sexual events in controlled populations. Neuroimaging and behavioral research suggest involvement of limbic structures linked to reward anticipation. Activation of melanocortin signaling → ↑ dopaminergic transmission in mesolimbic pathways. This central mechanism positions PT-141 as a neuroendocrine modulator rather than a vascular agent. Evidence type: Human RCT ✔ | Observational ✔.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSelective MC4R And MC3R Receptor Agonism:\u003c\/b\u003e\u003cbr\u003ePT-141 selectively binds melanocortin-4 receptors (MC4R) and melanocortin-3 receptors (MC3R) expressed in hypothalamic and limbic regions. MC4R activation triggers adenylate cyclase → ↑ cAMP production → modulation of downstream dopamine signaling. Preclinical models confirm behavioral changes associated with receptor stimulation. This receptor-level specificity differentiates PT-141 from hormonal therapies that broadly alter endocrine balance. Research also indicates interaction with pro-opiomelanocortin (POMC) neurons → modulation of motivational circuitry. These receptor interactions underpin its central arousal profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eDopaminergic Reward Circuit Enhancement:\u003c\/b\u003e\u003cbr\u003eMelanocortin receptor activation influences mesolimbic dopamine pathways projecting from the ventral tegmental area to the nucleus accumbens. PT-141 administration has been associated with ↑ dopaminergic activity in reward-processing regions in animal models. Dopamine plays a central role in sexual motivation and anticipatory behavior. This pathway differs fundamentally from nitric oxide-mediated smooth muscle relaxation. By acting upstream in motivational circuitry, PT-141 influences desire rather than only physiological response.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIndependence From Nitric Oxide Vasodilation:\u003c\/b\u003e\u003cbr\u003eUnlike PDE-5 inhibitors such as sildenafil, PT-141 does not primarily increase nitric oxide production or inhibit phosphodiesterase enzymes. Its mechanism does not rely on peripheral vasodilation of penile smooth muscle. Instead, central melanocortin activation → ↑ neural arousal signaling, which may secondarily influence physiological response. This distinction allows evaluation in populations where vascular function is not the primary limiting factor. Research highlights mechanistic divergence from traditional erectile function compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFemale Sexual Desire Research And Regulatory Validation:\u003c\/b\u003e\u003cbr\u003eClinical studies in female populations with hypoactive sexual desire research diagnoses demonstrate measurable improvements in desire-related endpoints. Phase trials report statistically significant ↑ sexual desire scores compared to placebo. These effects are centrally mediated and not dependent on hormonal replacement mechanisms. Regulatory approval in certain jurisdictions reflects controlled human data supporting this pathway. Evidence type: Human RCT ✔.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMale Arousal Signaling And Behavioral Response Models:\u003c\/b\u003e\u003cbr\u003eIn male research populations, PT-141 has been associated with enhanced erectile response secondary to central activation. Preclinical studies show ↑ mounting behavior and ↑ copulatory motivation in animal models. These behavioral changes occur independently of direct smooth muscle relaxation mechanisms. Central dopaminergic activation is considered the primary driver of these effects. Evidence type: Human studies ✔ | Animal ▣.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePOMC Neuron Activation And Melanocortin System Engagement:\u003c\/b\u003e\u003cbr\u003ePT-141 activates pro-opiomelanocortin (POMC) neurons within the arcuate nucleus of the hypothalamus. POMC activation → release of melanocortin peptides influencing motivational and reward circuits. This engagement extends beyond sexual signaling and interacts with broader appetite and reward biology pathways. The melanocortin system plays a key role in behavioral drive regulation. This systems-level activation distinguishes PT-141 from peripheral-only agents.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNeuroendocrine Integration Without Direct Testosterone Modulation:\u003c\/b\u003e\u003cbr\u003ePT-141 does not directly increase testosterone production or replace androgen pathways. Its effects occur independently of gonadal hormone elevation. This allows central arousal signaling without broad endocrine disruption. Clinical endocrine panels demonstrate minimal direct hormonal alteration under therapeutic dosing in research settings. The mechanism remains neurocentric rather than systemic hormonal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePredictable Subcutaneous Pharmacokinetics:\u003c\/b\u003e\u003cbr\u003eProvided in a stabilized pre-mixed injection pen for SubQ administration, PT-141 demonstrates reliable systemic absorption in clinical research. Subcutaneous delivery supports controlled plasma concentration curves and predictable onset windows in human trials. This route allows rapid engagement of central melanocortin pathways. Each unit is prepared fresh and intended strictly for research use only.\u003c\/li\u003e\n\u003cli\u003e\u003cbr\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Data\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse;\" cellpadding=\"10\" cellspacing=\"0\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStudy\/model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReported effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 randomized, placebo-controlled trials (RECONNECT; premenopausal HSDD)\u003c\/td\u003e\n\u003ctd\u003eImprovements in sexual desire and reduced distress versus placebo (endpoint-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term extension study (human; continued evaluation)\u003c\/td\u003e\n\u003ctd\u003eLonger-duration safety\/tolerability characterization with maintained efficacy signals in assessed endpoints\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroimaging\/sexual brain processing study (MC4R agonism; controlled design)\u003c\/td\u003e\n\u003ctd\u003eChanges in sexual cue processing and related central measures consistent with melanocortin-linked mechanisms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypothalamic activation models (animal; neural activation markers)\u003c\/td\u003e\n\u003ctd\u003eIncreased hypothalamic neuronal activation signals following melanocortin agonist exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMelanocortin receptor pharmacology (in vitro binding\/functional assays)\u003c\/td\u003e\n\u003ctd\u003eAgonist activity across melanocortin receptor subtypes with emphasis on MC4R\/MC3R functional outputs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurobiology\/mechanism reviews (integrated evidence)\u003c\/td\u003e\n\u003ctd\u003eProposed MC4R-driven presynaptic activation leading to dopaminergic facilitation of desire circuits (model-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety signal literature (clinical labeling and observational reports)\u003c\/td\u003e\n\u003ctd\u003eTransient blood pressure effects, nausea, and focal hyperpigmentation noted in regulatory documents and reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial registry dose\/design documentation\u003c\/td\u003e\n\u003ctd\u003eStructured trial designs detailing endpoints, populations, and administration paradigms for controlled evaluation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStack Suggestions\u003c\/h2\u003e\n\u003cp\u003eIn extended experimental designs, PT-141 (Bremelanotide) is sometimes paired with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eKisspeptin → to co-study upstream reproductive-axis signaling markers alongside central desire endpoints\u003c\/li\u003e\n\u003cli\u003eOxytocin → to explore social bonding\/affiliative signaling readouts in parallel with arousal circuitry measures\u003c\/li\u003e\n\u003cli\u003eMelanotan II → to compare melanocortin agonist profiles and receptor-selectivity differences in CNS arousal models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eHuman safety data exist from clinical development and approved-use labeling for bremelanotide, but outcomes remain dependent on study population, administration context, and endpoint definitions. Reported tolerability signals in clinical sources include nausea (often early in exposure), transient increases in blood pressure with reductions in heart rate, flushing, headache, and localized injection-site reactions; focal hyperpigmentation has also been described in labeling and reports. Experimental designs typically account for cardiovascular and gastrointestinal tolerability endpoints and avoid over-interpreting effects outside controlled conditions.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6819021\/\"\u003eBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)\u003c\/a\u003e — Human RCT\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6819023\/\"\u003eLong-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder in Premenopausal Women\u003c\/a\u003e — Human (Long-term extension)\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9525110\/\"\u003eMelanocortin 4 Receptor Agonism Enhances Sexual Brain Processing in Women With HSDD\u003c\/a\u003e — Human RCT\/Neuroimaging\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33455598\/\"\u003eThe neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2694735\/\"\u003eMelanocortin Receptors, Melanotropic Peptides and Penile Erection\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12851303\/\"\u003ePT-141: a melanocortin agonist for the treatment of sexual dysfunction\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210557s000lbl.pdf\"\u003eVYLEESI (bremelanotide injection) — FDA Prescribing Information (Revised 06\/2019)\u003c\/a\u003e — Regulatory\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210557Orig1s000Approv.pdf\"\u003eFDA Approval Package Letter — NDA 210557 (Vyleesi, bremelanotide)\u003c\/a\u003e — Regulatory\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/jwh.2020.8460\"\u003eRECONNECT Exit Study Results (post-trial follow-up analyses)\u003c\/a\u003e — Observational\/Follow-up\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/clinicaltrials.gov\/study\/NCT01382719\"\u003eClinicalTrials.gov: Bremelanotide in Female Hypoactive Sexual Desire Disorder (Study record)\u003c\/a\u003e — Clinical registry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003c\/li\u003e\n\u003cli\u003eIf you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.\u003c\/li\u003e\n\u003cli\u003eDiscontinue use if sensitivity occurs.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Peptoora","offers":[{"title":"15 mg","offer_id":61559776018762,"sku":"PE-LH-PEN-001","price":399.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/PT-141_10mg.png?v=1775793991","url":"https:\/\/peptoora.com\/es\/products\/pt-141-bremelanotide-pen","provider":"Peptoora LTD","version":"1.0","type":"link"}